Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04311606 · ClinicalTrials.gov registry record · Phase 2
Anti-VEGF Therapy for Acute Thyroid Eye Disease
A Phase 2 study of Thyroid Eye Disease, sponsored by Massachusetts Eye and Ear Infirmary.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT04311606: Completed Phase 2 study of Thyroid Eye Disease, sponsored by Massachusetts Eye and Ear Infirmary.
NCT04311606 is a Phase 2 study of Thyroid Eye Disease that has completed, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 11 participants, below the 106-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04311606, a Phase 2 study of Thyroid Eye Disease, has completed, sponsored by Massachusetts Eye and Ear Infirmary.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this clinical trial is to assess the safety and tolerability of sub-tenon aflibercept in combination with either saline or hyaluronidase (HA) in patients with acute Thyroid Eye Disease (TED) as assessed by the incidence and severity of adverse events from baseline to day 45. Participants will undergo clinical examinations and receive three injections of aflibercept with saline, aflibercept with hyaluronidase, or hyaluronidase.
Primary Outcome
To assess the safety and tolerability of sub-tenon aflibercept in combination with either saline or hyaluronidase (HA) in patients with acute Thyroid Eye Disease (TED) as assessed by the incidence and severity of adverse events
Conditions Studied
Interventions
- DRUG Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept
- DRUG Sub-tenon injection of hyaluronidase (HA) followed by a sub-tenon injection of aflibercept
- DRUG Sub-tenon injection of hyaluronidase (HA) alone
Study Locations (1)
Massachusetts
- Mass Eye and Ear - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2020-11-02 |
| Est. Completion | 2024-12-17 |
| Phase | Phase 2 |
What the finished NCT04311606 record still lists
NCT04311606 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 106-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Thyroid Eye Disease appearing as the primary indexed condition, and to 3 interventions - of which Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept is the first listed.
NCT04311606 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04311606 about?
NCT04311606 is a clinical study titled "Anti-VEGF Therapy for Acute Thyroid Eye Disease". The primary objective of this clinical trial is to assess the safety and tolerability of sub-tenon aflibercept in combination with either saline or hyaluronidase (HA) in patients with acute Thyroid Eye Disease (TED) as assessed by the incidence and severity of adverse events from baseline to day 45....
What is the current status of trial NCT04311606?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2020-11-02. Estimated completion is 2024-12-17.
What conditions does trial NCT04311606 study?
This clinical trial studies the following conditions: Thyroid Eye Disease.
What interventions are being tested in trial NCT04311606?
The interventions under investigation include: Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept (DRUG), Sub-tenon injection of hyaluronidase (HA) followed by a sub-tenon injection of aflibercept (DRUG), Sub-tenon injection of hyaluronidase (HA) alone (DRUG).
Who is sponsoring clinical trial NCT04311606?
This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04311606 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04311606's enrollment target sits among peer trials
11 16th of 15 the lowest of 15 other Thyroid Eye Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thyroid Eye Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease
RECRUITING · Phase 2
-
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
RECRUITING · Phase 2
-
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)
RECRUITING · Phase 1
-
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
RECRUITING · Phase 1
-
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI